Achieving Impact with Innovations at CU Anschutz
 

Lily Elizabeth Feldman , PhD

Full Faculty Innovations Program Director

CU Innovations

Postdoctoral Research Fellow

Department of Pharmacology

University of Colorado Anschutz

 

Learning Objectives

At the conclusion of this presentation, participants should be able to understand:

• Define the mission of CU Anschutz Innovations and its institutional role in supporting the transition of academic research into clinical applications ("Technology Transfer").
• Describe the comprehensive resources available to faculty for the advancement of new technologies, including strategic guidance and internal funding mechanisms.
• Identify the specific research and clinical milestones that warrant formal consultation with the institution’s specialized development and partnership teams.

Dr. Subramanian reports financial relationship as a consultant for ACELYRIN, Alexion Pharma, Amgen, GenSight Biologics, Invex Therapeutics, Kriya Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, an investigator for Amgen, GenSight Biologics, Immunovant, Invex Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, recipient of a research grant from Amgen and a DSMB member for Argenx. All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of AMA PRA Category 1.5 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.